BMS-986144

pan-genotype HCV NS3/4A protease inhibitor

proj. oral QD dosing, well-tolerated in rodent

deuteration reduced CYP TDI

J. Med. Chem., Nov. 23, 2020

Bristol-Myers Squibb, NJ + MA + CT + IN

Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.